<SEC-DOCUMENT>0001193125-13-250915.txt : 20130708
<SEC-HEADER>0001193125-13-250915.hdr.sgml : 20130708
<ACCEPTANCE-DATETIME>20130607090112
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-13-250915
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20130607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Correspondence</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g548369g50n70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;7, 2013 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">VIA EDGAR and FedEx </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Jeffrey&nbsp;P. Riedler </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assistant Director </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities and Exchange
Commission </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Division of Corporation Finance </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">100 F Street, N.E. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, D.C. 20549 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RE:</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dynavax Technologies Corporation </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Form 10-K for the Fiscal Year Ended December&nbsp;31, 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Mr.&nbsp;Riedler:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On behalf of Dynavax Technologies Corporation (the &#147;<B><I>Company</I></B>&#148;), we hereby respond to the comments received from the
staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated May&nbsp;30, 2013, (the &#147;<B><I>Comment Letter</I></B>&#148;) relating to the Company&#146;s Annual
Report on Form 10-K, File No.&nbsp;001-34207, filed with the Commission on March&nbsp;8, 2013. The text of the Staff&#146;s comments has been included in this letter in italics for your convenience. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information currently available and provided in the response is solely for fiscal year 2012, the year with respect to which the Comment Letter
applies, but the Company expects to provide disclosure in a form to be used in the future following acceptance by the SEC. Accordingly, we respectfully advise the Commission that where the Comment Letter requests the Company to revise disclosure,
such disclosure shall be the form of disclosure the Company intends to make in the 2013 filings of its Annual Report on Form 10-K. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Pharmaceutical Partnerships and Other Funding Agreements, page 7 and </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I><U>Notes to Consolidated Financial Statements, page 60 </U></I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please provide draft disclosure to be included in your next Form 10-K that provides the following material information regarding each of the noted collaborations:
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the AstraZeneca agreement, please disclose the aggregate milestone payments remaining to be paid and provide more specific information about the
royalty provisions. For example, you may either provide a range of royalties (within ten percent) or a statement that the percentage is in the single digits, teens, etc. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note your statement on page 7 that under the GlaxoSmithKline agreement you will receive &#147;tiered, up to double-digit royalties&#148; on sales.
Please provide a more narrow range for the royalties you will receive (within ten percent). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Proposed Disclosure:
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Item&nbsp;1. Business: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AstraZeneca AB </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2006, we entered into a three-year research
collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
asthma and chronic obstructive pulmonary disease for which we received an upfront payment of $10 million. In 2008, we received a substantive milestone payment of $4.5 million for the nomination
of the first candidate drug, AZD1419, for asthma. The research term of this agreement was extended through July 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
October 2011, we amended our agreement with AstraZeneca to provide that we will conduct initial clinical development of AZD1419. Under the terms of the amended agreement, AstraZeneca will fund all program expenses to cover the cost of development
activities through Phase 2a. In the fourth quarter of 2012, we and AstraZeneca agreed to advance AZD1419 towards a Phase 1 clinical trial. If AstraZeneca chooses to advance the program following completion of Phase 2a, we will receive a $20 million
milestone payment and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. We are eligible to receive additional milestone payments, which we have determined to be substantive
milestones, of up to approximately $100 million, based on the achievement of certain development and regulatory objectives. Additionally, upon commercialization, we are eligible to receive tiered royalties ranging from the mid to high single-digits
based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any. AstraZeneca has the right to sublicense its rights upon our prior
consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent early termination, the agreement will expire when all of AstraZeneca&#146;s payment obligations expire.
AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GlaxoSmithKline </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop and commercialize TLR inhibitors. We received an initial payment of $10 million and agreed to conduct
research and early clinical development in up to four programs. In 2011, we earned $15 million in milestone payments for the initiation of Phase 1 and proof-of-mechanism clinical trials of DV1179 in systemic lupus erythematosus patients and
expansion of our collaboration with GSK to develop a TLR8 inhibitor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are eligible to receive future development milestone
payments which we have determined to be substantive milestones. GSK can exercise its exclusive option to license each program upon achievement of certain events and we are eligible to receive contingent option exercise payments. If GSK exercises an
option, GSK would carry out further development and commercialization of the corresponding products. We are eligible to receive tiered royalties ranging from the mid single-digit to mid teens on sales of any products originating from the
collaboration and have retained an option to co-develop and co-promote one product under this agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent early
termination, the agreement will expire when all of GSK&#146;s payment obligations expire. Either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement. Either party may
terminate the agreement in the event of insolvency of the other party. GSK also has the option to terminate the agreement without cause upon prior written notice within a specified window of time dependent upon the stage of clinical development of
the programs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notes to Financial Statements: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AstraZeneca </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2006, we entered into a three-year research
collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The deliverables under this arrangement did not have
stand-alone value and so did not qualify as separate units of accounting. We received an upfront payment of $10 million. In 2008, we received a substantive milestone payment of $4.5 million for the nomination of the first candidate drug, AZD1419,
for asthma. The research term of this agreement was extended through July 2010. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011, we amended our agreement with AstraZeneca to provide that we will conduct
initial clinical development of AZD1419. Under the terms of the amended agreement, AstraZeneca will fund all program expenses to cover the cost of development activities through Phase 2a, estimated to total approximately $20 million. We received an
initial payment of $3 million to begin the clinical development program. In the first quarter of 2012, we received a $2.6 million payment to advance AZD1419 into preclinical toxicology studies and these toxicology studies were completed in the third
quarter of 2012. We and AstraZeneca have agreed to advance AZD1419 towards a Phase 1 clinical trial, which resulted in a development funding payment of $6 million, received in the fourth quarter of 2012. If AstraZeneca chooses to advance the program
following completion of Phase 2a, we will receive a $20 million milestone payment and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. We are eligible to receive additional
milestone payments, which we have determined to be substantive milestones, of up to approximately $100 million, based on the achievement of certain development and regulatory objectives. Additionally, upon commercialization, we are eligible to
receive tiered royalties ranging from the mid to high single-digits based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any.
AstraZeneca has the right to sublicense its rights upon our prior consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from the 2011 amendment has been deferred
and is being recognized as the development work is performed over the estimated performance period of approximately 50 months. The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance of research activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, and December&nbsp;31, 2011, deferred revenue from the initial payment and
development funding payments was $7.7 million and $4.9 million, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent early termination, the agreement will
expire when all of AstraZeneca&#146;s payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party
commits an uncured material breach of the agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GlaxoSmithKline </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop and commercialize toll-like receptor
(&#147;TLR&#148;) inhibitors. Under the terms of the arrangement, we agreed to conduct research and early clinical development in up to four programs: the Lead TLR 7/9 program, a Follow-On TLR 7/9 program, and up to two other TLR programs.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently conducting a Phase 1 clinical trial in the Lead TLR 7/9 program with DV1179 in systemic lupus erythematosus
patients. The Company is not currently performing any activities on the Follow-On TLR 7/9 program or the other TLR programs under the agreement. If we were to achieve certain development objectives in the Company&#146;s Follow-On TLR 7/9 program and
other TLR programs, we are eligible to receive up to $12 million in development milestone payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GSK can exercise its
exclusive option to license each of the four programs. If GSK exercises an option, GSK would carry out further development and commercialization of the corresponding products. If GSK exercises their option, then we are eligible to receive payments
of up to approximately $125 million for each program, comprised of contingent option exercise payments and additional payments based on the achievement of certain development, regulatory and commercial objectives. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also eligible to receive up to $60 million if aggregate worldwide annual net sales milestones are achieved and tiered royalties
ranging from the mid single-digit to mid teens on sales of any products originating from the collaboration. We have retained an option to co-develop and co-promote one product under this agreement. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We received an initial payment of $10 million in 2008. The deliverables under this
arrangement did not have stand-alone value and so did not qualify as separate units of accounting. In 2011, we earned and recognized $12 million in substantive development milestone payments related to the initiation of Phase 1 and
proof-of-mechanism clinical trials of DV1179 in systemic lupus erythematosus patients. Also, in 2011, we earned and recognized $3 million in substantive development milestone payments related to the expansion of our collaboration with GSK to develop
a TLR8 inhibitor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from the initial payment from GSK was deferred and is being recognized over the expected period of
performance under the agreement, which is estimated to be seven years. The following table summarizes the revenues recognized under our agreement with GSK (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012 and 2011, deferred revenue relating to the initial payment was $4.2 million
and $5.7 million, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent early termination, the agreement will expire when all of GSK&#146;s payment
obligations expire. Either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement. Either party may terminate the agreement in the event of insolvency of the other party.
GSK also has the option to terminate the agreement without cause upon prior written notice within a specified window of time dependent upon the stage of clinical development of the programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company acknowledges that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Company is responsible for the adequacy and accuracy of the disclosure in the filing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the
filing; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of
the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please contact me at (510)&nbsp;665-7217 with any questions or further comments regarding our responses
to the Staff&#146;s comments. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dynavax Technologies Corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="32"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jennifer Lew</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Lew</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cc:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray, Dynavax Technologies Corporation </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Ostrach, Dynavax Technologies Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Glen Y. Sato, Cooley
<SMALL>LLP</SMALL> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g548369g50n70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g548369g50n70.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1@$1`P$1``(1`0,1`?_$`+P```("`P$!`0$`````
M``````@)``H!!@<%!`(#`0`!!`,!`````````````````P0%!@('"`$0```&
M`@$#`@,$!0H%!`,```$"`P0%!@<($0`A$A,),4$4(A46&%%"%S=98:$R(R8V
M1D<9*22U=S@Y@5)#)76V5Q$``0($`P,)!08%`@4%`````0(#`!$$!2$2!C$3
M!T%187$BDM065H&AL3(4\)'!T2,5X4)R,S;Q-5)B)!<(@L)#4R7_V@`,`P$`
M`A$#$0`_`+@VT^T.><07.%HN%-7;7FQW*5]&<=6AFI*)UR+67?/&1(E8(V(=
MB=ZF5H"Q_)PD`$4+V^?2K:$*GG5E$-*JH=9D&6U.+/-L'7UPHS(7NU;DP%@F
MZI)43&..+#!OUHZ5@W]4L3^8AGB(<*-'9)2S)D!PEY`/=+@0X'N`].TL4Y&8
M9E)/2!^$0[]YJ6G-V6PE2=H)_+D^TX[MA;,_NU;%U!#(^-WV(&U+D'#QI&OY
MB$JT85XXC'2C!^1JR76DY,I47:!P$RW@41`?'D..DUII4JRD*'MGR=4/Z:IK
MJIH/(2T$F>TJY/9&XV[*GO#XA9&G+%CS&>285BF==\>HUUE/N`0(4ZRJB\;7
M)V(G"$0(00$R+90.._?X]99:(IRB>;GG_#E^W3Z\[<VDYDH;7_23,>PRG'RX
M2]YJO2LJUK^P.-E:/ZK@C-Q<*:X>R\1'+^8(J*359D$2ST>W14Y]4R*CLZ0`
M/*8\=8+I2/D,^O[8P@S>F5***A);4/;C/W2AUE:LU>N4!$VFJ3,=8:Y.LD9&
M(FHETD]CI!DN7R37;.43&3.4>X"'](I@$I@`0$`:D$&1VQ,)4E:0I!!2>41[
MG7D91.B")T01.B")T01.B")T01.B")T01.B")T01.B")T01.B")T01.B")T0
M1.B")T01.B")T01.B")T01.B")T01.B")T01.B")T01.B"*:V^G_`'C;"_\`
M4!Q_RR,ZD:?^T/;%-N_^X+ZD_`18/]J?_LLQ[_\`G[[_`/MTKTTJ/[IBP6C_
M`&]'M^)AC72,24(;]VW4*`;0)=H<>PK6*DVDBRC,M,8YN5NVEV<FJ5E%7)1%
M(I4B2C20.DU=J``"X36(<W)R"8SRF=_^-9PEA^7XQ!7BC"F_J6QVT[9<HYSU
M0*OM>[=2V&LJQ.%K7*+KXJRI,HQ<>W=KF.VI]ZD3%0BI1AZI_!E'V!UX-7J9
M?$@JJ)K<<E-Y95#>89Q\T-;/6J2X*5PS;([/0=LO;[I18"V.?[.1-:82NL\3
MC"P3,?\`>CJQ0&0SSB3N6;)-DE(UI5UHMPT9DD%%B*E.#I0A#"8@%$/M#TT1
MN\<\]F$HL+N_P+.7IGR^Z$H)^\]GF'>/(JRX4QN62CG;J/D&JC^UPSQA(-7)
MFSEH^;.%W?TZK-9,Q%"F`!*8._PZ=_2HEM,X@3>:E#A;<;2E<Y2)(EU]$.8U
MQN^R]^0>V'-]!Q71ZM*0D-)T@M"N+^WRLD:0*9RJZE'1DPB4X]5@HD=`4#F,
M(F'GMWZ:+2E)D#,Q.,+?6)O("1R2,Y_PYNB.BYM<YM:4D7&`(^@RM]3EXXQF
M&1WDJPKR\%_7_>I2.H@IG*4D']6*(F#T^/+R^77B<L^ULA9>?(=W(KEA/9[8
M7'KSN/N[L':9>&K&!\,'J](N)JI>\A'MMC0JX*Q[XC:91JKH%7(V&23;$453
M!N51$`.EZ@D`P<K+;;0)DG$8#"?MB.I:NJJ5*&1`2A1!5,R,N1(VSZX,;8^P
M;B5MPVDM;:1B6]0+>"57F(BYRTQ%VQ6;2<K#Z,(5!=I#NFIV'@)2JK)*"J`E
M#L(=)H#9P62(=5"JM(G3)0KK)!A-BGO&['UVTHQ5QQ)CEN2OS9XZYUTB5EB[
M`/T#GZ:6BVSAY*.4(B51.FH4HJHK$*H`>11#GIS]*@B8)QV1#"]N)=R/MY0#
MC+;[X>_@7/>.=C<>Q>1<;2Y7\8\*5"3BW`II3=:ERIE.Z@Y]B4YSLY!J)OTB
MFJ3A1,QB&`PM7$%M10J4^B)UEYNH;#K1F@QVCK"%83AM7M?O]K&S-:;!C#`C
MK'\C;E:[`V.$D+3-JF,]4?*U]I*QJ\E%/F;U\Q:\F.!#)>L4Q0$.2\N6D4ZS
M(E4_8/SB-K*BKIP5I2@M3&(..///#;RS@UM7Y7<.P-W]@V<B\35J*E(:.<UB
MLT8LPK9X]^X4]=R-D=.7[^(*D5D<I0114.H17GR-P''23@:!.[)V\OV_"';!
M?4B;X2%=$_M]T%STG"\!OO;L:^UDU[L5ZKKABE>I5_&U:AD?MT7K?\02BHJ'
M>KQZRB8/6\7%MG#@Y/@(D*`]AZ4:;WB\O)#2MJ/I:=3P^8;.D^^.<^W'ME8M
MI<23R^0G46ODZAV-2)LBD4P2B6LE$2J9I"MS"4:BHHDW]5`JS90"<%%5J(\!
MY=9/-[M4A/+TQA0UJ:QK-@'1M`Y/]8+C-*68U<?R@8&=4IKDHCF-4B#9`1D%
MZPLT3?(FE6SL(P0=IK+Q_F5(X=BGX$>DTY<PSSR\L/%Y\IW<L_)/9".\K^YW
MN?@'($[C#*F+L/-[3!?2'.+-"S_0/F+Q'UV4M&NR3AR/&$@D/)#`!1*)3%,`
M&*(`[##2P%()E+_6*^_=:NE=+3J$%8'3+'FZ.N#&U+S;O=LLVH^5I!IK_4L(
MR-B<)R[9NVLCNY3<%%/5V$LC$IA)/VT8]^J0.FD9P)!Y)Y"3Q$!%!U+2#E1F
MG$E2/552A+R@E+2N3:9?`?8P96?F>T2S>`>:US.)&;EF64&S0^4XR?=)S/J$
M:_=!(>0@UT_NX[<Y5O5%4#%/YEXX\1YP;+<_U`<O1MAVX'I@M%/2#L]V,*^P
MEN%[B>Q5XO&.J#2,!1#S'<HXA+M<)5K95:U7I!!^[C/2161L#DTTY6<,53HI
M-R'\TTQ,(E+WZ<+;80D%6:9$QL]_NY8C6:JM>?6RE*9(,B21(?=B</X\T.TK
MZ4VA!0R%E=L9"Q(Q;!.=?1C91G&O)@C5(LDZCVBRBJK9DN\`YDDS&,8A!`!$
M1#IJ93PP$2PG+';"G_<OWFR'K5.8XH.&)."9W*79/[9;59F':SR3>NE6".A(
M\&S@Q2M5Y5^BX.*@#ZA4D.P?:YZ798WB2HS`B,N-P-$4A"0I2OA]\Y^Z&,X$
MRU$9TP[C[*T*=+Z:XUQC(NVZ0\A'S)""UG8LX"(F(>-F$%D1`W?@@#\^DEH*
M%%)VB'S#R7V@ZG81'7NL(6@5MEI7;N&;PTAJ_6\3VI)NPE5K/#Y">2[&9=.T
MC-312-;5:/&,:?U4?6!0KE5/[?AP8`$>E6MSF_6GEZ(;O_42'T\I\LX3L_\`
M>7S[674O7K3@O'C.T0+QU$2K1Q(6R.6CI6-5.VD6LA&J++K)KHN$C`)`4+X\
M?$0[]+FE&T*[.WV1#&]/-DM/,R>GSRZIX0X35R[;'9&KCV\YJC,.Q5=L\17Y
MK&;;%TU,SXKQ\DT</'3F=E'QE&ARG35;@D#?R$.#^7?@.FZPA)DG-/EG$VRI
MY2`I[),C^4D_&`"V.W>W?U>F*HSR%B_7^2"]2LJTJ,75I^U34U))1[E!-(B\
M<1PU?HG<%?()D.5(Q3KG\"_:[=*MM-N"8)P&,1E76UU++,VV052$B9GV=/-R
M0;.N]SW:N]@8S6><88EQ?CQW7W#DD-"3DU+9`^^%P:J1?U:"CAU&QK<J1E0<
M(J&]<A@`.`$!#I)8:`D@DF'].NK5C4I2D$`B1V=!G^$&ETG#J)T0136WT_[Q
MMA?^H#G_`)9&=2-/_:'MBFW?_<%]2?@(L#>T^DHGIC2C'$!*O:;XJEP//"?X
MD=I<"'ZH^HD;M_Z_/IK4RWN'-$[9@H4(*MA42.K_`%G#(^D(E8'#<"#96/5K
M/\2_2(LV6Q3<W7@<.2@XC(9S*,U0[#]M!XS3.4?D8H#UFVH)6%&<@1LVQ@X@
M.-J;5\I!'NBEC'R+J/6CY=FJ9N]CW#*4:+IB)3H/&2R3ULL0Q1`Q3I+I%,'`
M\\AU*8>R*"E6[<"AM!B]E0YM:RT>FV-P``XL%4KLVN`!X@"TK$,WZH`7D>``
MZX]NH@RGALC8"9Y1/;*$!^[=J*>L6`=HJ)&\5VSNFD=EA@T3#PB;,MXM8JXB
MF4.",I\"D;/3\<%>`FH8>5C#T^IG<WZ1V@8?$Q`7BAS#ZIH$J'S=7/LY.69V
M1UKVDMO#3D6;5[(,L!Y>`:.)#$C]ZH85I&O-P,M*TXRZJ@BLZ@0,+AD7CR%F
M*A`'A`H=85#0'ZB-G+^<9VBO+H^E=F5I&!YQS>SD@U=S\PVDXUO53"+KU,[Y
MY17C1?MA.H&,<:&,*%MR','1Y.Q!*.!9%B(\&.MY&+]HA0,DRF1WJA-M/QY!
M]^WHB5?4<&48.+Y>8<I]G-RP4F$\/U#`V,*EBJCM/IH&J1J;0JZA2_6RT@H(
MKRDY)JE[N).7?J*+K'$1^T?Q#[)2@":E%:BI6TPJA"6T!M'R@1U3K&,XK,WC
M3F:VJV/WX"ERI8O(V-\EQDQ5H:2])O7[2SG6CY:3AWCH2@K&2+P[-,[1T/*(
M*&$%0\3^97X=2VVW/Y2DSEMG,_A*(*JM[=74.RFEY(2>@S!]\Q]T!9@;/.9-
M*,QOGS%A)1,C%R`P.2L:6`KABUG6C-<2N(V3:G`?I9)KR8[)Z0IA3,(&*)TC
MF*;-QH.)Z>0Q$4M546YTI4#E.U)^(_/EBV1KYL)CK93'<;D3'4G]0T7\6LW"
M.C)DG*M-%3*=U"3C0AC"@Y1$>4U`Y2<)<*)B)1[1ZD*0<JML6VGJ&ZEH.M'`
M^X\Q@,?=V8INM/9!X<"\P^2L=R!!$`Y**LJM%G$/F`@E(F^'Z.EZ/+]2D+V$
MR]IV1A6HSTY'(%)/W*!AD=94(M6Z^LF;S35@XE0APY^T0[!N8IN_`_:*//3<
M@@D';#K`[-D>YUY!"$_<"BKEN'LS^7'&SH%&.O\`BBT9&L0`FHX:N;F^CD';
M6('T3<?7NFGT3!#R`126=J?RAT[:_2:WBI8J]W+$)7@UK_T;1,D)*C+9F_E!
M_/I@`_;;SW^PG9RKEF72C&GY-`N.+6FN<44&;J5=I!6Y1V4X>*1HNPD324,(
M`)$EU`$0[]+/I"FCSC&(RTNEBLW2ABKLGH(^WY1;HZCHMT),]Y+`24_0JAL+
M",@&8H;M&H7)5(GVW%/G71C1+UQX$^T$)85`3`QA^R1\;Y!V<TRY+RGEV=<0
MUYIMY3[Y([:#CU<OW1S_`-F+.R289!UTFGOBJ=97)%$275X`Q#E;1]PBFI3\
MB8Y%"MGH$+QP!EC<?$0SJD$R7R;(2LE05MJIU?R[.HSPAOVS.7&&"L#Y0RD]
M6*DK5ZI)+1!1X$SFQ/4ACJZT3(//F9Q,ND"B'_MY'X!TV;1O%A'.8F7W0PRI
MT_RB!_\`;@PBOAG6.IN9UJ9*]Y245R?=G"Y?^,.^LY2.8EFY.;E3EA!^@`D'
M^BL=3YB/6;Z\[A(V#`0C1,EFG"5?.<3LVG$[(/!==%J@LY<*D1;MTE%UUE#`
M5-)%$@J*JJ&'L4B9"B(C\@#I&'<5)=F(&^[,%V!W;:*J.<<5[+L9C.#:'354
M5"H,VOW;&S#5;R!%*-CE#,@<!X@)EY(3?JFZD$2:*6C*9$SUQ5ZYE=6ERN2"
M$H(2!+:!@H]8/LE!V^S+GT`_'6N$Z]*`E%?(E`36.0HF(<S=G<8EN`\'.<BI
MF[TI`YX*=8WR'I*J0,%@=</+)4!;)IS/,DS'4?XP_+II$Y$Z((0Q[M.G8N$3
M;1XWA?)RV*DTS'&QZ0`*K$A4V\9>RMDP#S69F$&\D<H>1D136-SX*&Z>4S@D
M4+./)^./PB#O%&'&_J6Q^HG;TC^$<<]MOW`H3"T!.X;SA-JM<=P\3+67'M@4
M35=JPCIL59_)TKP)Y*JMYHYA5C2AV(Z,=(>"J%$N50T5G.,5$@0E:K@E+99J
M%'LB8GS`;/9R"#<U+Q-;-G<OO=\<_12K5HX.9GK7C>42\T*E3VQE"QMM=-U/
MZH9!R14ZC4PEY.X55==N6_BBM80C<M_^H\YB2IVU/._6O)*5RDD'D3/`F?*?
M9+9#;NF\/XG1!$Z((IK;Z?\`>-L+_P!0'/\`RR,ZD:?^T/;%-N_^X+ZD_`18
M*]J(5ATOHGJ``$"RWP$!#CDR/XH?B(FX$1Y]83AWX[!TTJ/[IB?M$_H$3V3,
MOO,,?Z1B3@3]Y[FSHFI.>9MXJ1,7./YBNL2&.4AG$E:B%KC!!+R$/-0SB3`>
M`[^)1'Y=*-)S.`'9.$*EW<,+=YDF*==0JTE<K/5J3"-E7DM:IZ$K$8U1#E5=
MY,/VT<B4H<<`!17\C#\"E`1'L'4G,)[7(/;%(IVU/OI;&U2HO55N&0KE=@:\
MV'R;0,+%PS<P@`"9"+8H,4A$```#E-`.HE1S**MDS%]2))`YA'S6^HUV^U:?
MI=NBFLY6;/%/(6;B7J8*-GL>^1,BND<![E-XF\B'+P=,X`8H@8`$!*BDYDX$
M0*2%)*58@Q3TV*Q19M+-GW];JM@>)O*/+0EXQO:"*>,C]S/3F?P2CPR8E\GS
M,45&CLO8JWIF'CP4XZDFW-ZB?*<#%.JF7;;5A3:I3F4D<T]A'NBP=[<M0&T8
MXD=L+T__`!5FC89_)25DLCEL1+[EKD%,/H.$IE?1Y.$9`,0B_5]%,0(8QB@(
M#Z91Z8NJ,]V/D3]IQ9:$%3(J7#-UP3ZAR)'0/?#(.DH>Q.B"%.:;R9G&_'N%
MMDRE!N-CIPF$P#ZWU,:@LP-P(#X^B;S,(?/X=+N(RLH)VF9]DY?A#1L@UCNV
M>5'_`+HZSO/H?4]JJXK9*Z5A5\VP#`Y*]9Q2*BRLK=`AC(5BWBD05'#$YOLM
MG7=9D<>WDGY)CXR[NU]J>0[?X1A742*QN6`=&P_A%<O$>7\YZ/YKD%VC*1K=
MHKL@$+D+'4\99&*LC!%3R/&2R"8BBNDLD;U6$@CY"3R*JD82B(&?K0AQ,IS0
M=A'V]T5EIRHME3-0(YQ_Q#[;.F'5;AY]QEMK[;V2<A4"1\5(5]1'5BK+Y4"3
MU.L:-MA$SQ$PW2_I<@Y,9LX*'T[M+@Y!_I%*U;;4S4HS8@&?6!%CJ:IIR@54
M(/8PZ]HPAK>,%OJ,:X\7Y,/KT:I+<G'DX^I`1Y^3#R/)A\N_\O357S'KA\T9
MMI(Q[(^$?TR/>H7&-!N60[$L1"$I=;E['(G.<">:$4R5=?3D,/(>LZ43*DF'
MS.<`Z$I*B$IQ48]4H(25*V`3BO=I/MXRQ-(9GRYD+"6;[[D3.US6LR]KIU16
MEX-.M@JX<L8:/>.#H'$C=^\6`_@)TS$22`!^QQT[>2V9!*@F0V'\_P#2(6DJ
M%H2IY++JU.*)F`-G)U[/?"UMC58MYFF]6RITVYX[K%PL;VWUB`N<(K7YF,"2
M7*\?%;-C!Z1F;2<,MZ!DS&`I/$!'D.G#:@4``S(PF(A:X+%47<BF\V(!P^WL
MBV-I9F]/8+6_&]_7<E<6$D26M7,H'$ZJ-NK0%C)<R_/V@4D!2(\+S_\`&Y*/
M?J/=2$N%(V3BW4KH?IT.@SFG'KY8[GDF@P&4Z!<<<VAN#F`NM=E*[)IB`"8C
M>3:J-P<H\]BN6:IBK)&_54(4?EUBE12H*&T&%E)"DE*L4D13@KLI>--MGFKQ
MR55.UX2R(LQED""HFE.1#-P=E*(!P)!5C[-6W)C$X'@2KE$/@'4D0EU&&*2,
M.>*<DNVNNZCLG@4G[??#Y-NK5%;8Y*U$UII$B,G3<EN(O8/(J[4Q%$AQ="-?
MKH9N_*0P^C]\&,X(!#CQZP)]N>.F;8+:5.$=H8#H/\(LE3^NZTRDS;)S*'.!
M*1GS3Y(;8BBBV12;MTDT$$$DT4$4B%32112(!$TDR%`"D33(4```[``=-]N)
MA_`$^Y/FMQAO5VW(0CE1&Y9.51QG52-O(SP%;&FJG-NVR1`%0YFL"1P!?$!,
M"JJ8!W$.EF$9ESPD,3#*OJ#3TY*<7%8)'*2>:%U8KV8Q52M0D-6IS6+8UXUD
MJ3,P5M?-L?BLA)6:P%<.I*P('4525Y2EUBJMA,0#I$12`0Y+UF9J7O"M.:<-
MDO*:8%.FG>4@)EB![>7GA3.#LE3FN^=*'D7Z>1CWU!M;52=C7C=S'OU8-4XL
M+)%/F2A4W"*CN$<K%,D<.0.(?H#IVI(=1EG@>6*[2NKI*L*4""#(@X=$C%V*
M$F8VQ0T38(9TD^B)R-8R\6]1,!T7<?)-DGC-RD8HB!B+MUBF`?T#U%G`RB\1
MZG1!'AV9:O(5R>6MIHPE62AY(]C--`@,.$&5FL,K]Z%<@+<S`6/GZP'`2"GR
M`]NO1.>&V,5%(22KY98Q2SSE08IC.6#)N+:K:HW7.WWZU0V)['/,_2:R*$0N
M!G3!DH`F,5FW.<_T8+<*&;$`HB8Z:@%E$D_(O^Y+'\XI=:W^LI]E)%.5=D\A
M.TR]O\(L;^VIN"VV(Q<2@6QR@CEK%D8PCI9(J:;<MGJJ!$V,+:F2*8%3]1,I
M"-7Y"``)N`*?L58H`R?:#:@4_*?MS?=%FMU8*MCM$;X;1\#[89CTWB0B=$$:
M1=,EX[QRS,_OUYJ=,:%1,X]:S6"+AO41(/B91$C]T@HN`&[?8`P\]NO0"HR&
M)C%2DH25*,DB*;FVE[KF3=ELU7RH//O*KV2]23N"D@(9,DE'H)-F*3]$B@%4
M*W>&:BHEY`!A3,`B`<\=2322AL).V*3<'DOU:W42*#*73(0W/VLMTL14C%AL
M!Y5M<;19J%L4U+5&;L*Y(^N3<1/.2/U8TTNJ4C*.EH^156'P<'(59(Y1(83`
M8O3>H:459TC`RV1.VFM8+":8D)<3SG;.9P_&&YV+9[72J12\W/9PQ8RC6Y!.
MHL2[U]\J8`(*GB@SCWSIZY4,4/LD33.<P]@`1Z;!"U'*D$JB74ZTE.=2@$2G
M.?)SQ7K]Q'?9CM"XA<1XB:RO[+HB:1DW,FY:.6\MD.S(@=O%%90WA]8A"QIE
MCF;I*%^H=+G*<2$`A2B]89+<UJ^?\(KMSN`J/^FICF1RD#;U?P@O?;+T`L5$
MF8[8O-\*>&L*+)4V,Z+)H^,I"#(H&07MEC:J!RPEC,U3),FI@]9`JAE3^!_`
M`2?>"NPGY>?\H>6NW+IB7WY!PB0',.6?VY(>7TUB:B=$$56O=R616W">BBLD
MKZ6-:,DIZ2A%/35*>;,9-3P,/@H!3`(E'@>!`?GT^I?D/7%7OQ!?1+_Z_P`3
M#N_;2.0VD6!RE.0QDX*=(J4IRF,FH%PL0F(H!1$2*!SW`>![]-',P<(5\TXL
M-,4FG042ED&SJQ]\'5UA"\3H@A->ELF@G[C>_L8+I#RD9%!ZW1]1+S6&*FT6
M;HR8<^H<4#O`*<"\@4?CQVZ>/$&E:EM$Q/K)PA@TZDU[K0VY4D_;V_:4.4Z9
MP_@!=X-%J;MA6#3,6#*KYHKS`Z=4N/I"1O*H)>:I*O;2HE%1["N5!$$EN#+L
M5#>:?)?-,Z[#VZ,B)H.WG]GVQAG64:*QO(K!0V'FBJ[:H[*.$Y;(^,+$C.TB
M9=LCU:_U9P<R3:69,WB$JQ([1^TSE6`/&J3MB[3\BB'"B1P`P\OAE<DL8@;/
MA%1>%31E=(LR!E,;0>8C[=$73L)J'6PSB-54PG55QC0E%#F[F.<]5BC',8?F
M)C#R/48KYCUQ=6<64'_E'PA;/NLY:2<4G'FKU6GX]K;\[7FOQD\/WDV0"#IS
M678)_43)C*%(S9R<XY;`7U1(51-NM\@'I:G2,Q<4#E3]OA#&Y+.5%,DC]50!
M'++\!TPT+'E.@\>42H42M$3)`U"N1%=B_2`@%4:Q3%%F1P;TQ$@K.?2%100Y
M\CF$?GT@3,DG:8DDI"$A*1)($A"L/>)PTPMV#J[EUJ+)"QXHG2-W!EED&[F2
MJ-K5;Q\BR0]0Y%'BK"6(T<D2*!C`0%3`'QZ<4JI+*.<?"(N[L!VD*_YD8C\8
M#OV=,^,:9D>Z8-L<HFQBLDMD+)41>.$T69;C!(BWD(](RQR)I.YR#,4Q0`>5
MCLBE`!,(<J5*)I"^;"&-DJ#-5,HC+M'/TR_*+(@"!@`0$!`0Y`0'D!`?@("'
M80'IE%CBO![R^!B0ULHVPT&R*1I;4242\*(I\`$]%-U'58DW!@^R)W\219J(
MCW_X0G?OT^IEIR;LDYYX<TOSG%>O=-@FJ3U'\#'9/9OQ%(A5;ML#:%';UW,D
M:8KQ\J_<'<FCZ955OJY=*/*KYBUCU9Q8B"1""!"_2'``X'I*H4/D3++.?MAU
M:&U[C?NDJ6K`3Y$C8!T0[L1`H"8P@4H`(B(B```!\1$1[``=-HEX2UE*SU_:
MGW,,18I2FHB1QSK=%OKK+)?>#=5C/7QL#2258M?ZPJ<@YC7IHU%5(@J>`(..
M0#@W3E!+;"CCVOM]C$6XXEZY(8"I;H%1Q&)E@)<X$R=DH=-TVB4BL/[ON&H^
MBY_ALG0ZC0C+,$%]1,1Z2J(.&]JJY&T:_>G:E.*I4)6+4:G%0Q0`RZ:G?GJ0
MIUJ4W([$Q6+ZR$NH>`^82/6-GN^$,K]J'/[')>NS'&DQ,-U+KA]V>L_0N5TR
M2#RG+B+NK/T$E%/6=-VB"AV)CE`0(+8H#QY%Y;U",JY@228E+55"HI@D_P!U
M&!_`^V&EF,4A3'.8I"%`3&,80*4I0#D3&,/```!\^F\2<);V.S@7=C/4+H_B
M&ZMX3&2+MU(9SR`Q?MTQLS&O*(K/J54U/4*$FBFN`)*F3$Y'#H0["@@<QW3:
M=TV7C\_)^<0[]2FKJ10-*D@?.><#^4=>&,,?R)K#B?(>!%-=G=?:Q5!9P#2'
MK"$>@D5>J.XE`20DY$G,`>,I'.!]45!'E<3*`H(@H?E`.+"]Y,YHDEL-K8-.
M1^D1*45/V4EE31O9ER9BZ;EO.)+0M'O2MUQ&'MT`KZ9UF;@4A'RAK5"+$,)1
M_K$#'`>`43[24PXWA\JA]W^D5.2[77C-BE)GARI/MVRYXMRX*SC1-A,;U_)-
M!DT'<=,,TC2$9]0BI)UR7*0H2$#,H)CYMI".<<D-Y%*"A0!0G)#%$8Q22A64
M[8MS3J'VPZV9H.R.Q=8PI`>;`:+Z_;-7.'O>5XBQR4]!PB5>9#%6>0AF0QB+
MUQ(%27:-."J*"X='Y/R!N.`Y[=*(=6W\AA!VF9?_`+R0KFGR=4<W0]K32A!%
M-$<6/UQ3(!167O-V,LJ(?KJF)/)D$X_R%`.LC4.DSG[A#8VN@)GNQ]Y_./YO
M/:PTG=H'0#%TBV\Q+RLVO-T*L``(")2BK-K$X-QP/V1[=>BH=29S]P@%KH`9
M[L?>3^,:I_I$:7`Y^H+5[N0OJ`H#8E_FP0*`"`^D7D17!/@./Z?E_+UE]4\%
M9L)]0_*%/V^BE+=I@FL0Z9:S8,?)3&.<35V-L"(@9*RR@.['84#@4"@=I+6!
MS).F!^`^+<4N>DENK</:.'-R0JS3,,"320,)3EC!0=)PO$Z((YCE[$]<S527
MM"M<C:XN$D'3)VY<4RSRM1FCF8JBJF@$Q#K(/"M%3=E4O+P4#L8!Z]!*2"-H
M@@-6WM5Z9I*'6>T>TS2ZB0D5<361+D]<*J#W%RHM][)*'<B/?R$1#O\`#IPN
MK>7BHB?0`/@(9N6^C=.9;8*N?$?`QN&,O;QU\P_=Z_>\?.<I03^MR1)1C#)Y
M.LRU777*DHD*,E!++G;2#10%1$Z2@B4YNYN>DU/+6,JI2G/8(412LMR#8*4I
M.`!,NG"<L8.CI*'$<!SQKI3]A6=88V^RY(KK>K/WT@S#'=WDZ6H_5D&R355*
M75C`%1\@D1(!2`1**9A$0'N/6:%E!G('K$XP4V%*"B2".8RVP*!/:AU40?+2
MS%?,$=-.#JJK3C'*UA2F%5EA$RRRL@8%%UE5E/M'$XF\C=QYZ4^H=D4X2/0/
M=S0@**F3BA.51VD$@GK(@YL38RAL.T*#QY7Y>TSL3``]!I)W.=<62Q+@_D'4
MBH#Z8<D36=`BJZ,1(!`/!(I2AV#I$DJ,SMAPE(2D)&P>V.C]>1E`8[9:.8BV
MZ:P:]R5EZM;*^*B#"ZU0(]*<5B'!3?40<D#]H[:24:*@@HD"I!.W5`13,4#'
M`RK3JFSABGFAI543%6F3HQYQM^^")#&D,IBEOB)U(39H%*C,J"K)L)%6'L"D
M6TA$8/ZQO)QGTZL?)J-D?/U4/`2*#R7CMTG,SS<L.<@"-V/EE+V0&K7VM--$
MVYTY&A62PO5#^:LS8,B7>0F%1`IB@"KP)M'S`!-Y=R\^7?I8U+I,R1]P'P$-
M';=2/*SN([4MLS^<$[@K7C&VN<#,5O&:-C;1$W)IR[QM8;7.VD4GB31)D7Z!
M2<>O#Q[<4$2\I(^"8F#GCGI-QQ3BLRI3E+``?"'B4A(RIV".092T%USS1>I7
M(.2XFYV>:F'39TX9NLAVYO7V_P!*R08I-HZ"9RC=A&M?20`QBHE()CB8PCR/
M6:7W$)R)E+J$_OE.$':2G?!#J<T^D_G'.I'VJ]+GJ9"ML?6"&63$3)NX>_7!
MNZ(IV$BA%'$LZ*4Z8AR40+V'KT5#HPF,>@?E"";90H,PV)]))_&#-Q'BNL85
MH$#C6G+3R];KA':<8:RSK^QRQ$GCUP_426E9)15TLDFLY,"91'Q3)P4```Z2
M4I2SF49F'J4I2))P$>-GG!U(V*QG-XJR`1_^'IM:-=F=1*Z+66CGT2^1?LGT
M:Z7;NDV[E-1'P$PIFY3.8OZW0A90K,-L)OLHJ&BROY2/NZ1'L8>Q14L'XUJ6
M*Z.BZ1K%-C`C8X7RQ7,@Y$ZZSMV]D')4T@</7SQPHJJ?Q*`F./``'`="U%:B
MI6V,T(2V@-H$D@2CPLY8(I&PE2:4J_N;6A!-9AM-BE4K5+5-T[<M4'+=-L_>
M0ZR"[N/,1T83('$2&,`"/<`Z];<4VK,F4^H'XP+;2X)*Z??A`MA[6^F*:*1&
MN.IQ@[1*3PE6&0KRUE04*/)E_JTY[D%UN1\S``<\_+I7ZET*S"75($?<8:IM
M](A8<2F2P=H)@U*ACZ`HU!B<;U]283KD)"&@(]1_-R4K-IL#)JI@96=D7#F3
M<.TRK#XK'4,<H@'`]@Z0F9YN6'83(91`5C[7>G[IT=]-T^WVAZHGX*.[+DR\
MRKHYA.*AEC.%)LBPJG.81'[7CW^'2WU#LLHD!U"&CEOI7CF=3F7SS,S]T?$I
M[5VGZ4BVE86L7>K/F:Z+ANO6LDV^-53.@<JI`*L,DNN!?4(!AX/R(_/CMT?4
M.RD9'K`ZN:/6Z"D9GNT2)Y9F?Q@A,[:KXYV(0K;._P`SD=K'UAH]9MXZHWV;
MJS"42?E:%5-/MHY0I)A9,&9?3.KR8GD?C^D/2:5E)F)>T3A=;*%IRJG*4MI&
M'L]_1`RE]IC3I%-O]%`7^.>-3E42E&&1[(WDBJ%`P`<%P7,F0_)N>2D*/(!_
M+RJ:IX@"8PZ!^4("WT2<0VD'GV$=1Z(*FRZU4>V89@<&2]CR=^$*^6-(A*L<
MAV"/NL@C%_4?3-YFW,UTI:4;F*Y$JA%#"50I"`8!\0Z0F09C;#K*,N4SE`T-
M?:GTT2*X%[2[9-N71%"JOYG(EN=OO44$1%SZZ<DAY."\]C&`W/S`>ES5/&1)
M$QT#\H:+MU$LYE-B<^GWXXQM>*O;FUTPM?83(F.C9+@9F"D?O)!@GD:=4@7Z
MGI+(E;3,48WA+L2D6[(KF.7DI1'D0ZP6\XX)*E+J'Y0JU2T["L[*<IER3E]T
MY0>/24.($;)NN.6;W=YBU5K<W8#%4))E9`TH5*A<).ZU"&:LF[18T<XMN*['
M8#_7+(F74!=XMPJH;Q\2<%"]V?5UEMEN;H:K3]JK:A$YO/*J@XN9)[6[J$(P
MG(22,`)XXQ2KOI:\7*O764M]N5&RN4FFDTQ0F0`.7>,+7B1,S4<29881H?Y0
ML[\_^1':GX!V_#FMWQ#XC^X_Y]2?G[3OI6Q]ZN\7$;Y(U#ZFO'=H_#1C\H6=
M^_\`N([4_`0#^SFMW8>1X']R'?@!_FZ//VG/2MC[U=XN#R1J#U->.[1^%C/Y
M0L[<\_ZB&U/';M^'-;OT#\_V'\]QZ//NG9?XK8Y_U5WBX/)&H9?Y/>)_T4?A
MHQ^4+._\1':GY?X<UN^7Q_R/_6Z//VG?2MC[U=XN#R1J#U->.[1^&C/Y0L[=
M_P#<1VI^?`?AS6[MV#C_`"/^0A_/T>?M.^E;'WJ[Q<'DC4/J:\=RC\-$#4+.
M_P#$1VI'N`_W<UN^'`=OW'_/H\_:=]*V/O5WBX/)&H?4UX[M'X:,?E"SOW_W
M$=J?GQ_9S6[MR/;_`"/^0='G[3OI6Q]ZN\7!Y(U#ZFO'=H_#1G\H6=N>?]1#
M:GC]'X<UN_0/S_8?^GH\^Z=]*V/O5WBX/)&H9?Y/>)_T4?AHGY0L[?Q$=J1^
M'^'-;OE\?\C_`-;H\_:=]*V/O5WBX/)&H?4UX[E'X:/S^4'/'?\`W$]J>X=O
M[-ZV]N_Q_<?WZ]\_:<]*6/O5WBX]\D7_`-37CNT?AHS^4+._/_D1VI^/P_#>
MMWPX`./W'_I[]>>?M.>E;'WJ[Q<>>2-0>IKQW:/PT8#4'/'`\^XGM2/P[_AO
M6WMQ\?\`(_Y]>^?M.>E+'WJ[Q<>^2;_ZFO'=H_#1G\H.=_XB6U/ZW^&];OG\
M/\C_`-7^?H\_:<]*V/O5WBX/)&H/4UX[M'X:,!J#GCY^XEM2/<!_NWK:';YA
M^X_Y]'G[3GI2Q]ZN\7`=$:@Y-37CNT?AHGY0<\?Q$MJ?AQ_=O6[X\\\_N/\`
MT=NCS]ISTI8^]7>+@\D:@]37CNT?AH@:@YX[<^XEM2/<>?[-ZV]^W8/W'_(>
MCS]ISTI8^]7>+@\D:@]37CNT?AHGY0<\?Q$]J?E_AO6WMQ\?\C_UNCS]ISTI
M8^]7>+@\D:@]37CNT?AHGY0<\?Q$]J?@(?W;UM^(_`?W'_J]'G[3GI2Q]ZN\
M7!Y(U!ZFO'=H_#1!U!SQWX]Q+:D._(?V;UN[!Q\.^#^CS]ISTI8^]7>+@&B-
M0>IKQW:/PT3\H.>/XB6U/P`/[MZW?'GGG]Q_S#MT>?M.>E+'WJ[Q<'DC4'J:
M\=VC\-$'4'/'R]Q/:D.XC_=O6T>P\<!^X_Y='G[3GI2Q]ZN\7`-$:@]37CNT
M?AHS^4'._P#$2VI_5_PWK=\OC_D?^M_-T>?M.>E+'WJ[Q<'DC4'J:\=VC\-&
M/R@YXX#_`'$]J?Y1_#6MO?O_`-#_`)='G[3GI2Q]ZN\7!Y)O_J:\=VC\-'Z'
M4+._\1':D.X_X<UN^8#P'[C_`)<]>>?M.^E;'WJ[Q<>>2-0^IKQW:/PT3\H6
M=N0'_40VIX_1^'-;N_8?G^Q#]/1Y]T[Z5L?>KO%P>2-0R_R>\3_HH_"Q@=0L
M[\?^1':D!_3^'-;OT@/_`/$/T=NCS]IWTK8^]7>+@\D:@]37CNT?AHR.H6=O
MXB&U(=P'^[FMWP^8?N/^?1Y]T[Z5L?>KO%P>2-0^I[QW*/PT8_*%G?M_N([4
M_+G^SFMW?CX_Y']O+H\_:=]*V/O5WBX/)&H/4UX[M'X:,CJ%G?\`B([4AW'_
M``YK=\P'@/W'_+GH\_:=]*V/O5WBX/)&H?4UX[M'X:)^4+.W//\`J(;4\?H_
M#FMW?L(?']A_/Q[]'GW3LO\`%;'WJ[Q<'DC4,O\`)[Q/^BC\-&/RA9W[?[B.
MU/S_`,.:W=^X<#^X_P"71Y^T[Z5L?>KO%P>2-0>IKQW:/PT9_*%G;GG_`%$-
MJ>._;\.:W?R<=_V'\]N/Y^CS[IV7^*V.?]5=XN#R1J&7^3WB?]%'X:-JHVL>
M8ZG<*Y99O>+8N_Q$+(I/9&DVB!P.A7K.V3*<IXN77KV(X6<19K"<!,+5VW5`
M2AP<._3*Y:SL5=0/4;&G+12ON((2\VJKWC9_XD9ZE2)C_F21SB'MNTE>Z*M;
MJJB_W2I90N9:<32A"Q_PJR4Z52/0H'I@R^M?1>HKN^ZG"6K*_N/>V_KBAF'-
M&+,>YB@\P,[M^QO(L[C^7??<S=M*Q[H'44L+4[MNLS`A5%D5O%(YP``YZZ9X
M0/T=HX7ZGU*JAH:RXT3K!:-2REY*9@@CM8@'E`(QCG?BJS4W+B+IRP)JJNFH
M:T/(<W#JFR0`5`X83!`Q(.$Q'1?:ORWFBI;8[U:!Y*RU;=@*;K-,5:>Q9E.]
MR'WY=6$!:@,5:DVFP"'JRCV/*JAX@H(F270<@7Q3,5-.)XNV>R5ND;!Q$M=$
MS;:RZ-K0^PTG(TI:`).-HV)!D=FT%$YG$R?"V[7FEU5>]"W"L<N%#;5H++SA
MS.@'`H6H;=HP.Q25RD,!PGW1\A[0^WAMI4=M<$SMIR!CK:BJ2^OTKAB>MTL\
MJ5;SZ^AS(8VM%8KT@X=QD2K)NVS=V)&J28+K,7:2AB%=`(6/A):]*<3-&OZ0
MU`ABFN=G>15IJ$MI#CE)G&^;6M(S*R@J1VIR"T$`E,0'$^NU1P\U4WJK3RW:
MB@NC2Z=3"EJ*$5)1)M:$DD"9"5I``$TN`_.(<YI)@:X:X:QX]QMDB_VC)V4B
M1CFRY1O%LL,G9)&8R#9SFEK(FR?2;IVJA!Q#Q?Z)@BD)$2-6Y!*4!,;G1FO=
M0T6I]5U-SME.S2VG,&V&VT);2&6^R@E*0.TH=I1.,S([(W-HJQ5FG-,,6ZXO
MNU%SREQYQ:U+)=7VEA)42<J3V4]`GM)BF50]W]I,`ZR[1US+F3<I2N.=QJ=G
M/\LV47%QM,Q/4/-N(,A.:Y)52,L2CQ65K)9R'(0ID4%2II"9HJ7Q`ZW7<ETT
M!I+4NI[366*DI&[G9':3ZY@-(2AZFJ&@L.*0!E5E5,@D8@+!G(2XWMNN-26&
MPW*GO-14&SW9MX4KV=Q2FWV'`%)"IS0%IP5)0^9LCEB\!C2V-*_KEC^]6^55
M*PA,)U2V6>;D5SKK%:1M%83$U*/G2YS*+*@BBJJJH<PF,/(B//7!-WHEU.JZ
MJW4*/U'+@XVVA(Y5/*2A(`Z2`!':UHK44^E:6XUBCNT6]MQ:B<9!E*E*)/42
M28JB>VIO5E>4]R6@Y!R?G,UOQM[@Z6;4('%`9`=V5KA&6B[W*CBZO2=1/+.V
MM'EI:.KB";,GT[8R[.1*(`/(]=A<4^']G1PMJ+;9[<&;EIOZ8KJ=R&U522TG
M?+"\H+J1G45&9DI!GLCE?AMK:ZJXD,5]SKM[;K\:@(8WF8L*WJ]VE:,Q#:IH
M2E``Q0L2VF'0^^'$958:/3.:<+W2YTN\ZXWVD9@%>G62:KZDS5XF72B[/$S*
M<.Y;_>\,FRE"O%FZX'2$C01$..>M%<`:BUKUZFQ7EABHH;G3.4\G6T+RN$9D
M*25`Y%=DI"ALS1NKC73W9.CC>;(\ZS76ZH0]V%J0%(GD5FD0%!.8+D9CLG#&
M.8Z>Y\G=[/<9MV;JA>[`KKYKQJ?B6LLJO!ST@G1)O-F=8M.]6=S+1+=RG&RD
MW388ZT:(N$U56JR/`"4>.I36VG6.'O#-FP5E.T-0W.[U#A6M*2\BFI5;IL!4
MLR4N$)<P("@H],0^C-0OZ[XANWJD=<_8K=:F$90HAM514I#BI@'*I38*T'"8
M*1T2U?WV\Z6Z,JFO&J&+\QML'7O/UUL=HF\BK7=7'J5:H.+*R_F54G]I;R<2
MO&-K397+1FEPL7ZA5(4^_/`O?_'JPT*ZVY:QO%`JX6RW,(;2R&M]G=?6$X(*
M5`E"`2<,`9PUX[7ZJ:I;?I2UUB:*XUSRW"X7"V$MLH)DI8(D%J.`*AF*98[(
M+;V;]F)':30#"]PL\PZF\@4EK(XHR'(2+PSZ3>V2AN?N]M*2#M559PZ=S5;4
M8/%%E!$RJJYC<C\>J9QQTHWI'B/74=*V&K;4%-0RD"02AT3*0)"00X%I`EL`
MBW<'-3G5.@J.J><+M=3@L.J)FHJ;^52CRE390HGG)A-?NW9RS/HCNC.FP=LB
M\B8?>+"[JJ7.E7.VVB9B-<)B1L,15#YRJT:+MZVIK=5N=9=H=NFGX.$WPE3$
M`1\=W\&K!9>(6A$"_P!L0I^PUZ7&G6VFTJK4I0I?TKBI`N\@5F)!&[F9SGIC
MBW>[SH/6:Q8Z\I8O=*4.MK<612J6M*2\@3DW.14@IQ2=YV2,L6<-<\81N&<&
M8MQE%7*P9%:5.G0[$<@6FP/;3/W=XLW!](6N1G9!V^<OSS[]THZ(/JG3325*
M1,?3*4.N4M479Z^:AJ[H^PW3..OJ.Y;0&T-`'*EL(2`!D`"3@"2"3B3'3VF[
M6U9K%2VUEY=2EME/ZJU%:G"1,K*B3/,22,9`2`P$=JZ@8FXJ@;!Z5S2/NP82
MU;9;E;K1>.]D<;Y>S9:5HS.LXSE:S/QK^[2[&!IGHD)%Q=7;GBTD2-U&RQTT
M0$I3_#KL;3NO:9?""NU:Y8;"NYVVI8ID9J5)2M,F$%3G\Q6=XI1((F91R??-
M&O-\6:+2K=WNZ;97TSM0N3Y!2K_J%94<@1-M,@09#`0V#W?92TXB]K'/SBB7
M6W05EIE(QY%0]V86"0C;@465VI40K)K6",69R!9&0:`?ZI9,Q!4]4_/8PAUI
MG@RBDO'%RW?7L4ZZ1^H>4II2`6>TTZK+D4",B3*0QD`.:-P\4U/6KAI6BD=>
M2ZRRTD.!9#ADXVF><$',H;3RS//`-^T)CEE9LEU7)4@Q]U.NV.JX?8V1[+;6
M9`?2>N&2).XP[.%DS4F,<'6-,AZDF>2B?5$IDFI2*\B8O?87&FZ&EM+UK95I
M!VG>K2@)M[(%8PEM16G>*_E^4-KEM)(Y8H'"&W(K:VGNS@U&W4-T:7":Q9-,
MZI:`E60$=H$J*T">P`\D=#]S[(>6<K;[:,^WK6LM7G">(\XQ=FOV6[)C2=<5
M&[VUE!*S9F52C+2U_P"+8H%2JZP&32'@ZKTAU"G!(A>HSA-;;-9^'M_XD5=%
M3U]XH%):80^G>--E0;FM2#@22Z,=H""$D$DP^XGW"[W;75EX?4U3445HK4EQ
M];*LBW!-R:`ODDEH@"4BI8)!($%M[>^#\TZTY!V2PQ<MIHC8?#D38X>8PM6[
M5D)W?,_8EB7Y'1WD#DAP\137;1TFBJB=J4P^/J(F43*4%C`%/XEW^PZKMEKO
MU#9UVR]K;4FI6VSNJ.H*0!F9Q.922#/EDJ1)RB+?P]LMWTY77*RU5S;K[2AT
M*80M[>U3`,^R]AV04E,ASI*A+,87+FO<?)>N7O.["M&U#V6V$HZNJ-":1^&\
M)%?6M*KRSY*!?+WQ2GNY9I#1C5(J*B"[Y(@+>JY*`^7(];*L&B;3J;@;;5N5
M%KMM=^[NE535205I2IP!K>!)4HG`A),I)C75YUC<=/\`&*XMBGN-=2?MJ`&J
M>:P@E#1SE$\HD9]J4P5=,%9[`F0;SDS1&4L^0K=;KI/*;#9B:)REVGI2Q3C6
M-1=02S*(4?R[IX[(A&_4&(5$#^"0^0%``ZJ/_D9;:"U:_:I;:RPQ3_ME.<K2
M$H053<!5)(`F9"9E,Q;.`MQK+GH==56N/..FO=`WJE*4!D:,IJ).TDRV8F$Q
M*[E;):P;7;Z9.O=[R!8-2LI9RV@U/6>/+389I'#.5&-7E;-BJ;K4>J[7+5$B
M+29&Z0L@3*HW!?@/4;I];Y.A-,:NT?IVT6REIV]94EOH+A)+:$_4TY4A%0EP
M@#/@"3F)[13/!1,:/3K34>F]4Z@KJ]ZH7I*HK:Z@S%Q2MP_E4MA21,J1E"@$
ME,NR%\J1%B[V^\C6EI[66O>5+)(S%UMT5K$E<I-_89-[+35CEH6OR<H/WG*O
M57#]ZZ>JLP(90YSG'GXCUS%Q/M=%_P!W[E9Z1"&*%5T#:4H2$I0E90.RD"0`
MG.0$HZ0T#<Z@<+Z*[NJ4]4(MZW)J)45%&<B9,R9R`VSBMV%NV97]NEQ[R:FW
M^=!V42V!3<IT)"].OV(IT<V2D*&;&AL9I^,.5B"*@+>F(>`-0],4Q$15ZZ><
MHM+)XEG@DFRV_P`KBV3WNZ`J2X&=[O@]BK-R3VE6,QLCG5RJU".'YXO?N];Y
MB-P`W8<E3[LNAO=[H@B0)S99RR=DB6,6.O<:R-9U/:RV"RE6Y.:H]JDM>&%O
MCY&`E'\).5R0FF\!(G"/E6"R$@Q=M/K#)@=-0IP[ASW'KESAS;*9GBU06BH2
MW44K=R6T0I*5H6$%:9E*@4J!E/$2CH/B/=*E7"JMN]*IQBI<HFG`4DI4DK4V
M2`001@H@X[)QWW0N8F;#I-J;/6*5DYR=F-><224O,S+QS(RTK(/:1#.'4A)/
MWBBKIZ]=K*"=150QCJ&,(B(B//4!Q%98I]>WABF0ANG1<J@)2D!*4@.*`"4B
M0`&P`"0B;X;OOU.@;/452UN5"[>R5*42I2B4"9*C,DGG,*7VH#)>Z?NS,M#9
MG.65<)Z^8MUM+F:2B\+7-Y0;9D.Z2KEJW:.9"=9IG7<LX0TP@)&X@HD0C500
M*!EC&+N31YM&AN#B^(#-NI*_4E7<OI@JJ;#K;+0S3"4SP*LAF<"2H3,D@'5V
MJC<-:<5QH*HK:NCL-/;B^4TZ]VIQ9"<5*D9R*TR$B!D,L5$QVGV1\\Y<R9BG
M8_#F7KM/Y1D-5MCKAAJJY-M3@[ZR6FFQYU30Z,Y)J"HK*/HD6JA074445%!5
M,AC#X`(P?'S3MGM-WM=\L].U1HO%L;J7&&\$-N&6;*G8G-,3``$P2`)F)S@I
M?[O=+9<;/=WU53EKKE,(>49J6@3`"SRJ!23_`$J`F90KO.N4YC9/-ON3Y8SY
MM-M%@W'&G&4:_@+7RIZY.+85"GV^4-9F4?D:[T^ED5E;5%J2U2%=^HIX>*#D
M2@J0I$BEVYIVT,Z6L.EK/IZT6BX7*\TZJJK=K`B;C:0TM333CO90K*]E0,<4
MSRSF8UA?+D[J:^ZANEZNEQH**T/IIZ5-.596UE3J4NK;1(J02R2HB2B%RS8)
M$6'_`&Z<KRF;-+\#Y#G,I$S7,RE47CI3*I:C)T56\/*[,R=?5G'E8F/_`+".
MD'`1@`X,<"_4+E,L!2@H!0YDXG6ABQZ[N5MIJ3Z&G0_--/O$NAH+2E>5*TX%
M(S=D?RB2>2.AN'MV<O6CZ*O=J?K'2A22]E*-X4+4C,0H`YI`!1D,R@52$Y0$
M/L7WF\7W`.R,E>[G;+O(QNYN;82.?VZQ2UC>1\*P"NBQB&+F7=NUFD6S%4WI
M()B5)/R'Q*'/5^_\@*"@H+_:D4##+"%V5A2@VA*`I14X"HA(`*B`)DXGEC7?
M`.Y5]QL=T57O.O*;NJTI*U%1"=VV9`J),IDF7.3":LD35ER1[BN_M1NY_=#R
M76Z?F:-BZ9"Z/Y#G&L'CUE)H>D\)<8QR^.QBHUSZ9#,2-DR!PDN(@/6[[0Q1
MVWAGIZMI!I2EJGJ,EQ=T925/%(!&[4`"I0F<Q43M$:LKWJFY\0[]25@U'4,L
MU<FQ0+.1L$D$+!F!.0D!(8&+2&3Z5EO'>DMQH&M<W8YG,M2P._KF))_)$VWE
M+E(6R.K`LX20LT_+E*S>VU58@&%PZ`$3/O$RG!.1ZY,M=QL]VU^S=-4(9;LK
MUQ#E0AE!#26RN:DH;3B&N3*G').6,=,W2AN]NT*];]-..KO+5`4L+>4"Z5A'
M9*U*P+AYSAFVQ6K]N/,;[%FW&O5%V.R5[CFONP5W7FZQD*H;$2:]_P`!;+WF
M71518-H0]F!%Y0DB21_)FLR;NDSN#()E=I@814ZGXGV-%WT5<Z_35-IBY:>I
MTH<971)W-71-)^9:@B8=)&"@HIDD*)098<X<.KTY:]7T%NU#47RAO[N9#R*F
M;E/5.*."4YPE38FH`*DYVLHSIQG</ZXBCL&$>^YWB;5')&SNIKK*VT^PNO.Q
MT77\@M]?HS7;'][N=SLJ+A5BI:G\8O1L89`?,)&/:)BGX>HW.=NHH($,4#"'
M07"2\ZPM>E+PW9[/;;GII;K1JU5C[#3:"`<B2'WFDJ2K;.1D0,1&BN*EGTM<
M]1VI=UNUPMM^0AP4J:1EUUQ<_G*2TRXH$)F)`@E,^2.J^U+5="Z;7\Z0.GV3
M+IEO(K;(*9]E[ME^)O\`!YKD;TJ60%BE=8W)%-HLXW;-S`\!$$&!6PN?J/(Y
MU_4XA.,%9Q%KJBWU&MJ1BBMAI_\`HFJ=3*Z8-83W:F''4DD9?F7FRY9`)E$W
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M9/\`NPY<K59VOW]-K9344B7T;A=,&TI;6ZZ7\@43E6D;P*!F`F681S+<[3PD
M/#--#<[HX+`;DZIJI++F]2_,EQ"6PR5E(3-*CD"3@9@Y8<7L94L3V#V^K_3K
M-E6[T+!CK75M&3^6ZC79.9O$9BEM5(_[RL3&N,*S,RZ[Z1J:!_J$4HI5=--9
M3A$IB\%TEIFNO%-Q,8KJ>B8J=0"YJ4FF<<2AI507%207"M*0$N'LDN`$@=HS
MQW#?*2T/\/G*1VJ=9L7[>@%]"%*6&`A/:R!)7VFQV@$Y@"=A&"5[3CCV*+3$
M:7P6%-A*-C'*5;R;BAUBB[:_TU>PYFR'<8Q&-:U^,R[$U_'\].Q)[',?3N7J
MD^SB_1>^13'1_K"=;THKIQ_I'K_47ZV5%79G:9\5+54Z&Z9EM68J53J6ZE*@
MA$TI#2G)ID<3(QI!^V<":H6=BPW)FEO;3S6Z=I6E+JGEC*`'TI:4M)4N2B74
MHDJ8P$Q%B+8MKB]Y@'-#/-TDWB,0.L77AKDV7<HJKI1E)7K<BE9)(&[=J^<+
M+LHLRBJ1$D%E3*E*!"'-P4>:-++N[>I:!S3Z"Y>TUC182#+,Z%I*$S)``*I`
MDD"4YD#&.C]2)M:]/UJ+XH(M!I7`\K$Y6R@YB``22!B)`F<I`F%O>RW1M&L?
M:ZWZ!T9S58\\U$V4WCZ^7BXU>>J-H):'%=@RQ\*\B;#3**\^[H^"21,V5(R,
MDH957A0QP.4NT^/5PXA7/5%-4<0J!NW5OT@#+3;B'49`M6904AQT9BH]H%4P
M`F8V$ZWX,4.AK?8*EC0]:JOI_JB7G5MJ;7G*4Y4E*VVSE"1-)`()*I':!J^V
M5/\`;'0WXCKOO/EJJ/LAOM=F<'C_``QGZN$0P9"4YO;GB[VZ0-GL-43I+VZR
M$R"Z!FJLR=ZFD)A(V`O!P6TC7<4E<-U6_05$ZFV)N16_54CDZI;A0`EI;:'-
MZEM*<IS!L))E-7)##6%'PM3KL5NO:ME5>:`);IZM!%,EO,>VE:D;HK*@J0*\
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M,T5)W(IOTI+RJ+4BUO"<J<PQ42U'1&I56CZE8/K=`RM?\U8X94F-/C;(63ZV
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MR^*=NK:JL<1JM%$L,TX0HH6U)^:BYD*$R!<,BL$Y4X8]KJ'N85G`5QTDSE7-
MH,D3V(\%R437"7W(58@Y*R3==9HW.NN(Y9E"Q%>M4@]%W-(MFYP38./%-4QA
M`I0$Q87A95W^AUY056F*5NMOB%N;IEQ:6T+):6%36M:$B22I6*A,B6.R)SB)
M2V>LT=64U_J5T=I4E&\>0@K4@!Q!$DA*R9JD,$G;/I@'=!\$8YI&5L563'.[
MON)YGJ3.E2"5,QWFS%6=JO@>7JKRH';P;DTU<L+4^H-FD3$'2<1!1D$@44(D
M5$#B)2#L3B/J&XU]HK*6YV#3-#7*?3O7J6IHG*M+@<!6,C-0XX2I79<[!D"H
MF6)&N.'MAME!>*2HM]]U%74X9.[:J:>K;IE(+1"3F=8;:`"3F1VA,A(3S'H?
MNDT;1[(%UUB@\_9IR;@G9_\`%,NXU4NN!:UD&V9F++D5BRS+*+AL>4:^.G,(
MJ[,U,/UC=N3UBCZ*Q?ZX!BN$5PU];:&ZOZ<H*6X:4W2!<&JIQENGR]K*2MYU
MH!4LWRE6'S)^6)KBE0Z*N%7;F;]6U-!J3.31N4J'G*B>9,PE++;BB,V64PDS
MGE,LT?3[6='TEH%GV@@M?LT9*SMLI^-(9QMC=\[UN^U/-![$H$L6`93<+D&C
MT1^VAD3E=BG](W72%8P^JL8?2`N'%RX:[N5):7]14%+;M+;E0H&J5QIRGR=G
M,0MEUT%4LOS%)E\J?FA7A?0Z.M[UQ8L=;4U^HM].L=J4.MU&8K<D%)>;;4$A
M6?8#CM5LC<:M1]44?=9SI>(?--P=[:2>L%<A;YA8U7FDZE7,7).:X,;<6%I-
M3DH5]*NEDFH"U3F'"Q15'E`.!\6-5<-7*X/4%O>H&1I!%U6MJJWB=XM_]2;1
M;WF8)$U=HM@8#M<[JEH=,#B?7UK5:Z=2JH`EVGW:LB&\K4EAS)E)D$]D+)FH
MX82'J^TE2]6Z'JO*0>H>8K7G'%1\T9-D7EUN59F*G,)7=X[C#6B`"*FZE2WA
MF<0J1(J:P,Q35\Q$JI^.R7&>OU7<M7-U&L:%FW77Z!E*6FW$NI+0*\B\R7'!
M-1S89IB0P'*XX546FZ#32V-+5CE=;OJW"7%H4VH.%+>9.52&S(`),\LB2<>0
M!U><;^V*EK'[F43E'86R.\1WO;&SR.?K1-4ZRH36$=AY%2`18P&,&2&/!EK5
M(5^3(V6:+1K2:37(=4IE5$?5`+Y0W7BRK5>DWK1:VTWFFL[::1M#J"FKHT@S
M6^=]E:2M&"@M3>4Y3(*E%'J;;PP3IS4[5QN*U6M^ZK-6M;2P::K*AE2V-U-P
MH5*10%I(G,E,S#2M(H+#%9TTP)7\+79_DC!L3BJ)94B]VJ*<P;ZU4Y)!<$YB
M;B)>&KSF.%TB)Q5278MA*7^D0`ZU#Q"J;_6:\N-3?J=-)J%=62ZRVH+#;DDR
M2E:5+"I82(4<>6-I:%8L=+HJ@I[(^JIL**4!MUQ)05MXS4I*DH(GC,%(PBNZ
M?"7LZC&+WP-RMHBZ)_F0&0<X,2QOL`.I7[<Q?%$D+^-2X3-%A!`ZX#@)(6XM
MNWUGI_:ZZ5_?^-@J$V]5BM)XA_MH2*HOT?U_TV/;W7U4\^W^2>?^2>$<]?LG
M""9KC>KEY*_<,WTVXJ_H?J,A[&]%/DEDV25/+_/RQ82WL@,'VG2C/%>SA>Y#
M&6!I;&:K2ZWZI1#F>?U:HF7CC)RD'#Q$'9',AZ?BB5--!BYY(;L3CN'-.@:F
M^4>NZ"JLU,FKOZ*J;;+B@@..25-*UJ4@)Y9DJ&.TQT%KRGL55HJNI[X^JFL*
MV`%NMI*RA.9.4I2A*B1/+@$G#HQA?OMJX0P_0KO1K!A?<_>_.6/BXJ=LJ%0\
MT8PS14\"GIKIK$#"R\#+W'#M)IX*QL>FD$4DD_`QT5#>BF<H#QLWBI?[S<;?
M4TU\L6GK?<S5I+SU+44;M6'`59DK2S4..]I7]PE.!&)$:VX7V*R6^OIG[)>[
M[7V_Z4AEJHIZINFW92,JD*<8;:D!+(`K'^41^_<*QEI7DK;C$S21V0SSKIOC
M'XTF5:E+:MTG*%YR/.8A5/+A(-;3&X]QS>V244W$CX6YW2C-R"9C\>HGX`7S
MAE=M>6K1M8MJU4%TX>*JD[Q-<]3LLHJ!DD6U//-',?TY@!29RV&<.N(ELT5<
M=54B7KE76[6Z6"4&B:?=>6QE<F%AAIR0EO""2DRYQ*"<]JROZ5U;6I[`Z0WJ
M7R728[(MH0R3>+?'6F(R)8<N^$>:U/;[&W2LT^PLID4#-BIIFCV[<K<"`EY!
MY&&H\8*G7E7JA%1KZG12URJ5!8:;4VIE%/-60-*:6X@IGFF<Y5.<Y8"+1PJI
M]%TFFBQHFH55427U;UU:5I=4]).8NI<0VL'+E`!2!*6TS,+<V;PW[<]ZVOVJ
ML-5VYVGPED-A66Y=\Z!K!CS-EJI=AJ[=@W4D3Y#FJ7A^YP4.N_B_L2!FKU02
MF]83)IK>N/6S])7OB=;](6FFJK+::^VJ=/[4]7/4K;J'#/+N4NU#:U2/]L%(
MPE(E.6-<ZJL_#VNU5<ZEF[W2BK0R1<FJ-FI<;4V,N8NK:86E,Q@KM*$\V`5F
MALWMM5W7>JZ:8B@]4;_/Y.P$U3MJF/+E9XF6A)J1C'EUL+QTV=Q\[7*G+)EB
M9%=9HF==@@=5-`IQ\O+S-IGB=5:@K=;5E1JJE;H[\HM[YIM06A*@T@`A25N#
MM`!1`69$RY)1M?AO36"DT?3,:8J'*JR!3N[<6E2%&;JRH%*D(5V533,I$Y3C
MD_M54G5NC8AS5'ZHYDMF:JA);+Y1FKM.V^L2]5>U[)C[[F_%%/8,YFHTY=[%
M0H)H>BY31<)*^H/BNIP/$[Q?N&J[C=[>YJV@9M]6BULI:0VXEP.,@KRNDI<<
M`4HYII)!$OE$07":ATC0VRN1I"M=K:95>I3JEMK;R.[M`*`%H02`D),P""2<
M>0+3O6O&H%GW$W!GL2[][\8VS7+Y#1>;$4;6+#V;YR*JM@5;'+$1,G+4#!%C
M82+1N0JYF:AGKHH^2@%4-P;K:ENU-K&ET/9:>\Z;T[56%%/*D=KJJC0IQ(EF
M4E+]2A221ES`)2=F`PC6]TT[I2JUA=:FV:AO]-=%5,ZEFBIJM:$+F9)4IFG4
M#RR.8]!AO>6*Y@*.]O:<JNR.0<JV#`#7"$3#9$R;;XK(L=F25KJ;*.;)VZ=A
MH:L(9(9WE=[Z+E5`L0#PCGDJK;Q\R=:4M-5J)WB4BLTO2T;6HE5ZE,T[2F54
MJ53)W2%J<W!9"9IS;S*4XA6PQN*NI;$WP^-)?ZFJ<L8HT)<?<2ZFH4GLA+BT
M9-Z',V4D%N<_F3*8A2N!,'Z"T3.^E%ARCNCN)G!^=\5/0:A;+8RS;3\?-9)9
MFR"+6K$Q9L+U.,D'31B+,67USYHD/#40(?\`JBCN74E_XAW#3U\I;78;+0=D
M_N[U'44KKY`)SYT(J5J3,YLV5"S+-B,3&I[!9-"4-_LS]TO5WKGY?_FM5;%4
;VUB4Y2A2V$H(!R99J2GY,",HBRYURM'2L?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
